Literature DB >> 20673917

Stress hormones during flooding therapy and their relationship to therapy outcome in patients with panic disorder and agoraphobia.

Anja Siegmund1, Luisa Köster, Anna M Meves, Jens Plag, Meline Stoy, Andreas Ströhle.   

Abstract

In spite of excessive fear during a panic attack, studies have found no or little evidence for an activation of cortisol during natural panic attacks. Whether this phenomenon is related to psychopathology or outcome of psychotherapy is unknown. In this study, 10 patients with panic disorder and agoraphobia were treated with cognitive behavioural therapy including 3 in-vivo exposures (flooding) to individual phobic situations. Before, during and after exposure, the level of subjective fear was assessed and blood was collected simultaneously. Cortisol and ACTH were analysed from plasma. Ten matched healthy control subjects went through the same procedure. Fear and stress hormones during exposure were compared in patients and controls as well as related to therapy outcome at the end of therapy and 2 follow-ups in patients. Results showed that the concentrations of cortisol and ACTH did not significantly increase during exposure. Patients' cortisol concentrations were higher than those of controls at baseline and during exposure, while ACTH concentrations were comparable before and during exposure, and even lower than those of controls at recovery. Cortisol concentrations were moderately but consistently correlated to therapy outcome, i.e. patients with least cortisol release during exposure profited least from therapy. The study showed that a lack of stimulation of the HPA system at repeated confrontation with the phobic situation was related to therapeutic outcome. Mechanisms of action via the influence of cortisol on extinction learning or the inhibition of central excitatory neurotransmission are conceivable.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20673917     DOI: 10.1016/j.jpsychires.2010.07.002

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  16 in total

Review 1.  Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition.

Authors:  Borwin Bandelow; David Baldwin; Marianna Abelli; Blanca Bolea-Alamanac; Michel Bourin; Samuel R Chamberlain; Eduardo Cinosi; Simon Davies; Katharina Domschke; Naomi Fineberg; Edna Grünblatt; Marek Jarema; Yong-Ku Kim; Eduard Maron; Vasileios Masdrakis; Olya Mikova; David Nutt; Stefano Pallanti; Stefano Pini; Andreas Ströhle; Florence Thibaut; Matilde M Vaghi; Eunsoo Won; Dirk Wedekind; Adam Wichniak; Jade Woolley; Peter Zwanzger; Peter Riederer
Journal:  World J Biol Psychiatry       Date:  2016-07-15       Impact factor: 4.132

2.  The Future of D-Cycloserine and Other Cognitive Modifiers in Obsessive-Compulsive and Related Disorders.

Authors:  Michael L Sulkowski; Daniel A Geller; Adam B Lewin; Tanya K Murphy; Andrew Mittelman; Ashley Brown; Eric A Storch
Journal:  Curr Psychiatry Rev       Date:  2014

Review 3.  Cognitive enhancers for anxiety disorders.

Authors:  Stefan G Hofmann; Jasper A J Smits; Anu Asnaani; Cassidy A Gutner; Michael W Otto
Journal:  Pharmacol Biochem Behav       Date:  2010-12-04       Impact factor: 3.533

4.  Smaller volume of right hippocampal CA2/3 in patients with panic disorder.

Authors:  Masao Takaishi; Takeshi Asami; Haruhisa Yoshida; Ryota Nakamura; Asuka Yoshimi; Yoshio Hirayasu
Journal:  Brain Imaging Behav       Date:  2021-02       Impact factor: 3.978

5.  The psychology of HPA axis activation: Examining subjective emotional distress and control in a phobic fear exposure model.

Authors:  Stefanie E Mayer; Michael Snodgrass; Israel Liberzon; Hedieh Briggs; George C Curtis; James L Abelson
Journal:  Psychoneuroendocrinology       Date:  2017-02-09       Impact factor: 4.905

6.  Endogenous in-session cortisol during exposure therapy predicts symptom improvement: Preliminary results from a scopolamine-augmentation trial.

Authors:  Kate R Kuhlman; Michael Treanor; Gabriella Imbriano; Michelle G Craske
Journal:  Psychoneuroendocrinology       Date:  2020-03-20       Impact factor: 4.905

7.  Long-lasting increase of corticosterone after fear memory reactivation: anxiolytic effects and network activity modulation in the ventral hippocampus.

Authors:  Anne Albrecht; Gürsel Çalışkan; Melly S Oitzl; Uwe Heinemann; Oliver Stork
Journal:  Neuropsychopharmacology       Date:  2012-09-12       Impact factor: 7.853

8.  Antianxiety medications for the treatment of complex agoraphobia: pharmacological interventions for a behavioral condition.

Authors:  Giampaolo Perna; Silvia Daccò; Roberta Menotti; Daniela Caldirola
Journal:  Neuropsychiatr Dis Treat       Date:  2011-10-19       Impact factor: 2.570

9.  Stress-induced cortisol reactivity as a predictor of success in treatment for affective dimensions.

Authors:  Andres D Roque; Michelle G Craske; Michael Treanor; David Rosenfield; Thomas Ritz; Alicia E Meuret
Journal:  Psychoneuroendocrinology       Date:  2020-03-07       Impact factor: 4.905

10.  Hydrocortisone as an adjunct to brief cognitive-behavioural therapy for specific fear: Endocrine and cognitive biomarkers as predictors of symptom improvement.

Authors:  Susann Steudte-Schmiedgen; Emily Fay; Liliana Capitao; Clemens Kirschbaum; Andrea Reinecke
Journal:  J Psychopharmacol       Date:  2021-04-28       Impact factor: 4.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.